Early detection and treatment strategies for breast cancer in low-income and upper middle-income countries: a modelling study

Jeanette K. Birnbaum, Catherine Duggan, Benjamin O. Anderson, Ruth Etzioni

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Poor breast cancer survival in low-income and middle-income countries (LMICs) can be attributed to advanced-stage presentation and poor access to systemic therapy. We aimed to estimate the outcomes of different early detection strategies in combination with systemic chemotherapy and endocrine therapy in LMICs. Methods: We adapted a microsimulation model to project outcomes of three early detection strategies alone or in combination with three systemic treatment programmes beyond standard of care (programme A): programme B was endocrine therapy for all oestrogen-receptor (ER)-positive cases; programme C was programme B plus chemotherapy for ER-negative cases; programme D was programme C plus chemotherapy for advanced ER-positive cases. The main outcomes were reductions in breast cancer-related mortality and lives saved per 100 000 women relative to the standard of care for women aged 30–49 years in a low-income setting (East Africa; using incidence data and life tables from Uganda and data on tumour characteristics from various East African countries) and for women aged 50–69 years in a middle-income setting (Colombia). Findings: In the East African setting, relative mortality reductions were 8–41%, corresponding to 23 (95% uncertainty interval −12 to 49) to 114 (80 to 138) lives saved per 100 000 women over 10 years. In Colombia, mortality reductions were 7–25%, corresponding to 32 (–29 to 70) to 105 (61 to 141) lives saved per 100 000 women over 10 years. Interpretation: The best projected outcomes were in settings where access to both early detection and adjuvant therapy is improved. Even in the absence of mammographic screening, improvements in detection can provide substantial benefit in settings where advanced-stage presentation is common. Funding: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Cancer Center Support Grant of the US National Institutes of Health.

Original languageEnglish (US)
Pages (from-to)e885-e893
JournalThe Lancet Global Health
Volume6
Issue number8
DOIs
StatePublished - Aug 1 2018
Externally publishedYes

Fingerprint

Breast Neoplasms
Colombia
Standard of Care
Drug Therapy
Mortality
Neoplasms
Therapeutics
Eastern Africa
Life Tables
Uganda
National Institutes of Health (U.S.)
Estrogen Receptors
Uncertainty
Survival
Incidence
Research

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Early detection and treatment strategies for breast cancer in low-income and upper middle-income countries : a modelling study. / Birnbaum, Jeanette K.; Duggan, Catherine; Anderson, Benjamin O.; Etzioni, Ruth.

In: The Lancet Global Health, Vol. 6, No. 8, 01.08.2018, p. e885-e893.

Research output: Contribution to journalArticle

Birnbaum, Jeanette K. ; Duggan, Catherine ; Anderson, Benjamin O. ; Etzioni, Ruth. / Early detection and treatment strategies for breast cancer in low-income and upper middle-income countries : a modelling study. In: The Lancet Global Health. 2018 ; Vol. 6, No. 8. pp. e885-e893.
@article{122df87b230c41018d0b714b200693c3,
title = "Early detection and treatment strategies for breast cancer in low-income and upper middle-income countries: a modelling study",
abstract = "Background: Poor breast cancer survival in low-income and middle-income countries (LMICs) can be attributed to advanced-stage presentation and poor access to systemic therapy. We aimed to estimate the outcomes of different early detection strategies in combination with systemic chemotherapy and endocrine therapy in LMICs. Methods: We adapted a microsimulation model to project outcomes of three early detection strategies alone or in combination with three systemic treatment programmes beyond standard of care (programme A): programme B was endocrine therapy for all oestrogen-receptor (ER)-positive cases; programme C was programme B plus chemotherapy for ER-negative cases; programme D was programme C plus chemotherapy for advanced ER-positive cases. The main outcomes were reductions in breast cancer-related mortality and lives saved per 100 000 women relative to the standard of care for women aged 30–49 years in a low-income setting (East Africa; using incidence data and life tables from Uganda and data on tumour characteristics from various East African countries) and for women aged 50–69 years in a middle-income setting (Colombia). Findings: In the East African setting, relative mortality reductions were 8–41{\%}, corresponding to 23 (95{\%} uncertainty interval −12 to 49) to 114 (80 to 138) lives saved per 100 000 women over 10 years. In Colombia, mortality reductions were 7–25{\%}, corresponding to 32 (–29 to 70) to 105 (61 to 141) lives saved per 100 000 women over 10 years. Interpretation: The best projected outcomes were in settings where access to both early detection and adjuvant therapy is improved. Even in the absence of mammographic screening, improvements in detection can provide substantial benefit in settings where advanced-stage presentation is common. Funding: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Cancer Center Support Grant of the US National Institutes of Health.",
author = "Birnbaum, {Jeanette K.} and Catherine Duggan and Anderson, {Benjamin O.} and Ruth Etzioni",
year = "2018",
month = "8",
day = "1",
doi = "10.1016/S2214-109X(18)30257-2",
language = "English (US)",
volume = "6",
pages = "e885--e893",
journal = "The Lancet Global Health",
issn = "2214-109X",
publisher = "Elsevier BV",
number = "8",

}

TY - JOUR

T1 - Early detection and treatment strategies for breast cancer in low-income and upper middle-income countries

T2 - a modelling study

AU - Birnbaum, Jeanette K.

AU - Duggan, Catherine

AU - Anderson, Benjamin O.

AU - Etzioni, Ruth

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Background: Poor breast cancer survival in low-income and middle-income countries (LMICs) can be attributed to advanced-stage presentation and poor access to systemic therapy. We aimed to estimate the outcomes of different early detection strategies in combination with systemic chemotherapy and endocrine therapy in LMICs. Methods: We adapted a microsimulation model to project outcomes of three early detection strategies alone or in combination with three systemic treatment programmes beyond standard of care (programme A): programme B was endocrine therapy for all oestrogen-receptor (ER)-positive cases; programme C was programme B plus chemotherapy for ER-negative cases; programme D was programme C plus chemotherapy for advanced ER-positive cases. The main outcomes were reductions in breast cancer-related mortality and lives saved per 100 000 women relative to the standard of care for women aged 30–49 years in a low-income setting (East Africa; using incidence data and life tables from Uganda and data on tumour characteristics from various East African countries) and for women aged 50–69 years in a middle-income setting (Colombia). Findings: In the East African setting, relative mortality reductions were 8–41%, corresponding to 23 (95% uncertainty interval −12 to 49) to 114 (80 to 138) lives saved per 100 000 women over 10 years. In Colombia, mortality reductions were 7–25%, corresponding to 32 (–29 to 70) to 105 (61 to 141) lives saved per 100 000 women over 10 years. Interpretation: The best projected outcomes were in settings where access to both early detection and adjuvant therapy is improved. Even in the absence of mammographic screening, improvements in detection can provide substantial benefit in settings where advanced-stage presentation is common. Funding: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Cancer Center Support Grant of the US National Institutes of Health.

AB - Background: Poor breast cancer survival in low-income and middle-income countries (LMICs) can be attributed to advanced-stage presentation and poor access to systemic therapy. We aimed to estimate the outcomes of different early detection strategies in combination with systemic chemotherapy and endocrine therapy in LMICs. Methods: We adapted a microsimulation model to project outcomes of three early detection strategies alone or in combination with three systemic treatment programmes beyond standard of care (programme A): programme B was endocrine therapy for all oestrogen-receptor (ER)-positive cases; programme C was programme B plus chemotherapy for ER-negative cases; programme D was programme C plus chemotherapy for advanced ER-positive cases. The main outcomes were reductions in breast cancer-related mortality and lives saved per 100 000 women relative to the standard of care for women aged 30–49 years in a low-income setting (East Africa; using incidence data and life tables from Uganda and data on tumour characteristics from various East African countries) and for women aged 50–69 years in a middle-income setting (Colombia). Findings: In the East African setting, relative mortality reductions were 8–41%, corresponding to 23 (95% uncertainty interval −12 to 49) to 114 (80 to 138) lives saved per 100 000 women over 10 years. In Colombia, mortality reductions were 7–25%, corresponding to 32 (–29 to 70) to 105 (61 to 141) lives saved per 100 000 women over 10 years. Interpretation: The best projected outcomes were in settings where access to both early detection and adjuvant therapy is improved. Even in the absence of mammographic screening, improvements in detection can provide substantial benefit in settings where advanced-stage presentation is common. Funding: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Cancer Center Support Grant of the US National Institutes of Health.

UR - http://www.scopus.com/inward/record.url?scp=85049754428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049754428&partnerID=8YFLogxK

U2 - 10.1016/S2214-109X(18)30257-2

DO - 10.1016/S2214-109X(18)30257-2

M3 - Article

C2 - 30012269

AN - SCOPUS:85049754428

VL - 6

SP - e885-e893

JO - The Lancet Global Health

JF - The Lancet Global Health

SN - 2214-109X

IS - 8

ER -